{"i": ["perioperative immunomodulation", "IL - 2", "antimemetic metoclopramide", "interleukin - 2", "antipyretic metamizole", "perioperative immunomodulation with IL - 2 ( IL - 2 group ; n = 60 ) and perioperative immunomonitoring without immunomodulation as a control group ( control", "IL - 2 group : three ; control group : one ) mistletoe treatment", "Perioperative immunomodulation", "systemic immunotherapy", "surgical resection of lung metastases", "IL - 2 group ) IFN - \u03b1 and vinblastine , and one ( IL - 2 group ) local immunotherapy with inhaled IL - 2 .", "immunochemotherapy ( Hanover regimen : IL - 2 , IFN - \u03b1 , 5 - FU ),", "fluorescein isothiocyanate", "adjuvant immunotherapy", "metamizole and metoclopramide", "interleukin - 2 ( IL - 2 )", "tumour nephrectomy", "Interleukin - 2", "perioperative immunomodulation with IL - 2 ( IL - 2 group ; n = 60 ) and perioperative immunomonitoring without immunomodulation ( control group", "Recombinant human IL - 2 ( Aldesleukin , Chiron", "immunomodulation with interleukin - 2 ( IL - 2 )", "perioperative", "IL - 2 - based immunotherapy", "immunotherapy"], "o": ["Interleukin - 2 - related toxicity", "progression - free survival", "tumour - specific survival", "T - cell markers ( CD3 , CD4 , CD8 ), activation markers ( CD6 , CD25 , CD28 , HLA - DR ), B - cell marker ( CD19 ), and NK cell markers ( CD16 , CD56 , CD57 )", "Tumour - specific survival", "perioperative immunomodulation", "numbers of intratumoral lymphocyte subsets ( CD3 , CD8 , CD57 )", "progression - free survival .", "Frequency and severity of side effects", "tolerability .", "leucocytes , CD3 , CD4 , CD6 , CD8 , CD16 , CD25 , CD28 , CD56 , CD57 , CD69 , IL - 1 - RA , IL - 2 , sIL2 - R , IL - 6 , IL - 10 , TGF - \u03b21 , and VEGF", "elevation of T - cell , NK cell , and activation markers", "immunological parameters", "Progenitor cell marker CD34", "postoperative kinetics of B - cell marker CD19 and progenitor cell marker CD34", "median survival time", "Survival curves", "Tumour - specific and progression - free survival", "cellular and humoral immunity", "maintenance", "ECOG PS , tumour stage , Thoenes grade , histological subtype", "postoperative nadir of cellular parameters of the immune system", "T - cell markers , activation markers , and NK cell markers", "IL - 2 levels", "Median time to progression", "soluble IL - 2 receptor , IL - 1 - RA , IL - 6 , and IL - 10 .", "differential blood count , T - cell markers CD3 , CD4 , and CD8 , B - cell marker CD19 , monocyte marker CD14 , natural killer ( NK ) cell markers CD16 , CD56 , and CD57 , activation markers CD6 , CD25 , CD28 , CD69 , and HLA - DR , progenitor cell marker CD34 , and cytokine IL - 1 receptor antagonist ( IL - 1 - RA ), IL - 2 , soluble IL - 2 receptor ( sIL2 - R ), IL - 6 , IL - 10 , transforming growth factor ( TGF )- \u03b21", "perioperative immunodysfunction and survival .", "postoperative increase of IL - 6 and IL - 10", "perioperative immunodysfunction", "initial dose", "cytokines", "progression - free survival rates", "IL - 2 - related toxicity", "survival", "tumour recurrence", "tolerated .", "cellular and humoral immunity ( leucocytes , T - cell markers CD3 , CD4 , and CD8 , B - cell marker CD19 , monocyte marker CD14 , natural killer ( NK ) cell markers CD16 , CD56 , and CD57 , activation markers CD6 , CD25 , CD28 , and CD69 , progenitor cell marker CD34 , as well as IL - 2 , IL - 6 , IL - 10 , soluble IL - 2 receptor , IL - 1 receptor antagonist , transforming growth factor - \u03b21 , and vascular endothelial growth factor )", "survival benefit", "IL - 6 and IL - 10", "ECOG PS , tumour stage , Thoenes grade , and perioperative immunomodulation .", "median tumour - specific survival time", "alterations in parameters of cellular and humoral immunity .", "toxicity , tumour - specific survival , and time to progression .", "Monocyte marker CD14", "related toxicity", "tumour diameter , Thoenes grade , histological subtype , location , operation time , operative technique , or perioperative blood transfusions .", "leucocytes", "objective response and survival", "survival curves", "TGF - \u03b21 and VEGF", "elevated leucocyte and granulocyte but decreased lymphocyte counts , T - cell markers , activation markers , and NK cell markers .", "Median time to tumour progression", "died of recurrent disease", "leucocyte subsets", "toxicity .", "Toxicity"]}